Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.
| Revenue (Most Recent Fiscal Year) | $200.45M |
| Net Income (Most Recent Fiscal Year) | $-6.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.62 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.35 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 116.13 |
| Pre-Tax Margin (Trailing 12 Months) | -3.86% |
| Net Margin (Trailing 12 Months) | -3.27% |
| Return on Equity (Trailing 12 Months) | -1.66% |
| Return on Assets (Trailing 12 Months) | -1.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.22 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.55 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.93 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.97 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.05 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.05 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 127.22M |
| Free Float | 114.08M |
| Market Capitalization | $512.71M |
| Average Volume (Last 20 Days) | 1.14M |
| Beta (Past 60 Months) | 1.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.33% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |